Hypertension Diagnostics (OTCMKTS:HDII) & Integer (NYSE:ITGR) Critical Analysis

Hypertension Diagnostics (OTCMKTS:HDII) and Integer (NYSE:ITGR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Hypertension Diagnostics and Integer”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hypertension Diagnostics	N/A	N/A	N/A	N/A	N/A
Integer	$1.86 billion	1.60	$102.81 million	$4.01	21.87

Integer has higher revenue and earnings than Hypertension Diagnostics.

Profitability

This table compares Hypertension Diagnostics and Integer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hypertension Diagnostics	N/A	N/A	N/A
Integer	7.64%	12.83%	6.51%

Analyst Recommendations

This is a summary of recent ratings and price targets for Hypertension Diagnostics and Integer, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hypertension Diagnostics	0	0	0	0	0.00
Integer	0	6	4	0	2.40

Integer has a consensus target price of $98.29, suggesting a potential upside of 12.08%. Given Integer’s stronger consensus rating and higher probable upside, analysts plainly believe Integer is more favorable than Hypertension Diagnostics.

Insider & Institutional Ownership

99.3% of Integer shares are owned by institutional investors. 40.0% of Hypertension Diagnostics shares are owned by company insiders. Comparatively, 1.1% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Hypertension Diagnostics has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Integer has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Summary

Integer beats Hypertension Diagnostics on 9 of the 10 factors compared between the two stocks.

About Hypertension Diagnostics

Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. It offers CVProfilor, which allows a physician to non-invasively assess the elasticity of small and large arteries, of which small artery elasticity is the earliest and sensitive marker of cardiovascular disease. The company offers CVProfilor DO-2020, which provides a patient's arterial elasticity indices used in the assessment for underlying vascular disease; CVProfilor MD-3000 that offers a sensitive and specific guide to the presence of blood vessel disease; and HD/PulseWave CR-2000 research cardiovascular profiling system, which provides researchers and scientists with a non-invasive means to assess arterial elasticity in support of human research in various areas. Its products collect 30 seconds of blood pressure waveform data, perform an analysis of the digitized blood pressure waveforms, and generate a CVProfile report that contains information on blood pressure, heart rate, pulse pressure, body surface area, body mass index, and C1-large and C2-small artery elasticity indices. The company sells its products to primary care physicians, cardiologists, health care professionals, trained medical personnel, research investigators at academic medical research centers, government institutes, cardiovascular specialists, and pharmaceutical firms. It markets its products through a representative organization in the United States. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.